Fortress Biotech (FBIO) EBITDA (2010 - 2026)

Fortress Biotech's EBITDA history runs 16 years deep, the most recent figure standing at -$4.8 million for Q4 2025.

• In Q4 2025, EBITDA rose 79.91% year-over-year to -$4.8 million; the TTM figure through Dec 2025 stood at -$70.4 million (up 36.17% YoY), while the FY2025 annual figure was -$70.2 million, up 36.38% from the prior year.
• EBITDA for Q4 2025 stood at -$4.8 million, up from -$6.8 million in the prior quarter.
• The five-year high for EBITDA was -$4.8 million in Q4 2025, with the low at -$62.0 million in Q4 2021.
• The 5-year median for EBITDA is -$36.5 million (2024), against an average of -$35.6 million.
• The sharpest annual moves came in 2021 and 2025: EBITDA plunged 155.12% in 2021, then jumped 79.91% in 2025.
• Fortress Biotech's EBITDA stood at -$62.0 million in 2021, then grew by 11.88% to -$54.6 million in 2022, then jumped by 64.1% to -$19.6 million in 2023, then declined by 21.52% to -$23.8 million in 2024, then surged by 79.91% to -$4.8 million in 2025.
• Business Quant data shows FBIO's EBITDA at -$4.8 million in Q4 2025, -$6.8 million in Q3 2025, and -$36.5 million in Q2 2025.